|Bid||13.31 x 0|
|Ask||13.75 x 0|
|Day's range||13.38 - 13.56|
|52-week range||10.23 - 14.27|
|PE ratio (TTM)||59.34|
|Forward dividend & yield||0.23 (1.68%)|
|1y target est||13.20|
Fisher and Paykel Healthcare Corp (ASX:FPH) has an impressive track record of growth to make investors take notice.
CSL Limited (ASX:CSL) and ResMed Inc (ASX:RMD) shares have been rated as buys by Goldman Sachs...
The shares of Telstra Corporation Ltd (ASX:TLS), Auscann Group Holdings Ltd (ASX:AC8), and Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) will be on watch on Thursday. Here's why...
Robust, high-growth companies such as NZX are appealing to investors for many reasons. They bring about a strong upside to your portfolio, and less downside risk as opposed to financiallyRead More...
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) due to its excellentRead More...
The Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) share price has sunk lower after the release of a strong full-year result. But is this the reason its shares are sinking lower?
Fisher & Paykel Healthcare has won a patent case against rival medical products manufacturer ResMed, after a court in the United Kingdom ruled the patent claim invalid. In 2016, New Zealand-based Fisher & Paykel sought a declaration from the High Court that three of ResMed's European patents were invalid in the UK and should be revoked. ResMed revoked two of its patents in the UK just before the trial was due to start, but left one for consideration by the High Court's patents division.